Results of HYD on the AACR Annual Meeting – Scientific recognition of deuterium depletion
Dr. Gábor Somlyai, head researcher of HYD Ltd. for Cancer Research and Drug Development and Dr. Laszlo G. Boros, professor of the University of California (UCLA, Los Angeles) participated in the annual meeting of the American Association for Cancer Research ( AACR ) in San Diego between 5th and 9th of April.
They presented the results of their joint research in the world's largest cancer congress having outstanding significance and great impact on the future of cancer medicine. This new understanding of the mode of action of deuterium depletion specified those biochemical mechanisms by which the anti-cancer effect of deuterium depletion is achieved. They also presented the effect of deuterium depletion in surgically non-curable pancreatic cancer patients. The results showed a sixfold increase in the median survival time (MST; 39 months) of patients who began to use deuterium depletion within 60 days after the diagnosis, while this value in case of patients consuming water with normal deuterium level was 6.88 months in women, and 5.86 in men. Both groups received the chemotherapy per protocol in accordance with the stage of their disease.
The presented poster, that aroused significant interest at the conference, can be downloaded here.
2014. april 16. wednesday